Skip to content

The mechanism of secretory phospholipase PLA2G12B mediating podococyte injury by regulating Notch3 signaling pathway in diabetic kidney disease

The mechanism of secretory phospholipase PLA2G12B mediating podococyte injury by regulating Notch3 signaling pathway in diabetic kidney disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089938
Enrollment
Unknown
Registered
2024-09-19
Start date
2024-09-19
Completion date
Unknown
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic kidney disease

Interventions

Diabetic group without nephropathy:None
Diabetic nephropathy group :None

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.18-80 years old; 2. Diagnosed with type 2 diabetes according to the 2010 American Diabetes Association (ADA) criteria. Diagnostic criteria for T2DM: A1c=6.5%; Fasting blood glucose FPG=7.0 mmol/l (fasting is defined as no calorie intake for at least 8 hours); 2h blood glucose = 11.1mmol /l during oral glucose tolerance test; In patients with typical hyperglycemia or hyperglycemic crisis symptoms, random blood glucose =11.1 mmol/l. If there are no symptoms of diabetes, repeat the test on another day. Type 1 diabetes, other specific types of diabetes and gestational diabetes were excluded.

Exclusion criteria

Exclusion criteria: 1. Combined with malignant tumor; 2. All kinds of non-diabetic nephropathy; 3.With severe gastrointestinal diseases (including peptic ulcer, hepatitis, inflammatory bowel disease, intestinal tuberculosis, severe diarrhea, constipation, etc.); 4. Combined with autoimmune disease; 5. Recently combined infection and fever; 6. Use of antibiotics within 3 months; 7. Patients with preeclampsia and eclampsia; 8Uncooperative patients

Design outcomes

Primary

MeasureTime frame
serum PLA2G12B;urine PLA2G12B;

Secondary

MeasureTime frame
Serum creatinine;Urine trace albumin;Glomerular filtration rate;Glycosylated hemoglobin;Renal histopathology;

Countries

China

Contacts

Public ContactCai Qian

Shandong University Qilu Hospital

caiqian@qiluhospital.com+86 185 6008 2223

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026